Squarepoint
FULC icon

Squarepoint’s Fulcrum Therapeutics FULC Stock Holding History

Squarepoint’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,900
Closed -$272K – 4865
2024
Q4 		$272K Hold
57,900
– – ﹤0.01% 4227
2024
Q3 		$207K Sell
57,900
-63,600
-52% -$472K ﹤0.01% 3670
2024
Q2 		$753K Buy
121,500
+101,400
+504% +$768K ﹤0.01% 2764
2024
Q1 		$190K Buy
+20,100
New +$179K ﹤0.01% 3629

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's FULC Position: Q2 2026 in Review

Squarepoint reduced its Fulcrum Therapeutics (FULC) stake by 28% in Q2 2026, selling an estimated $300K and leaving 126,558 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #3486.

Squarepoint first reported a position in FULC in Q1 2020 and has held it in 15 quarters since. The position peaked at $1.35M in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Squarepoint held 126,558 shares of Fulcrum Therapeutics worth $463K as of Q2 2026.
  • Squarepoint sold 49,386 Fulcrum Therapeutics shares in Q2 2026, an estimated $300K.
  • Fulcrum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3486 holding.
  • Squarepoint first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • Squarepoint's Fulcrum Therapeutics position peaked at $1.35M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.